目的:研究筋伤止痛活血散联合经筋刺法对急性软组织损伤后血流变及炎症因子水平的影响。方法:选取2021年3月至2022年7月于我院中医科就诊的急性软组织扭伤患者106例随机分为2组,对照组53例予以治伤软膏联合经筋刺法治疗,试验组53例患者...目的:研究筋伤止痛活血散联合经筋刺法对急性软组织损伤后血流变及炎症因子水平的影响。方法:选取2021年3月至2022年7月于我院中医科就诊的急性软组织扭伤患者106例随机分为2组,对照组53例予以治伤软膏联合经筋刺法治疗,试验组53例患者予以筋伤止痛活血散联合经筋刺法治疗。对2组疼痛程度、血液流变学指标、血清炎症因子指标及不良反应发生情况进行比较。结果:试验组治疗有效率96.23%,对照组治疗有效率77.36%,试验组有效率较对照组高(P<0.05)。治疗后,2组患者24、72 h视觉模拟评分(VAS)较治疗前降低(P<0.05);与对照组相比,试验组24、72 h VAS评分较低(P<0.05)。治疗后2组患者血液流变学指标水平较治疗前降低(P<0.05);与对照组相比,试验组血液流变学水平较低(P<0.05)。治疗后,2组患者血清可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)、肿瘤坏死因子-α(TNF-α)水平较治疗前降低(P<0.05);与对照组相比,试验组血清sICAM-1、sVCAM-1、TNF-α水平较低(P<0.05)。对照组与试验组不良反应发生率分别为5.66%、3.77%,无统计学意义(P>0.05)。结论:筋伤止痛活血散联合经筋刺法对于急性软组织损伤患者的止痛效果确切,能调节损伤后血流变指标,抑制炎症反应。展开更多
Objective:To study the therapeutic effect of Shangjinbitong Powder(伤筋痹痛散)on improving acupoint plaster,in order to provide some scientific basis for clinical use.Methods:This project was carried out from June 202...Objective:To study the therapeutic effect of Shangjinbitong Powder(伤筋痹痛散)on improving acupoint plaster,in order to provide some scientific basis for clinical use.Methods:This project was carried out from June 2020 to January 2021,30 patients with low back pain in the outpatient department of orthopedics and traumatology in our hospital and 30 patients with low back pain in the rehabilitation department of Fuping County Hospital of Traditional Chinese Medicine were selected as the research objects.Patients with low back pain in our hospital were treated with Shangjinbitong Powder as the control group,and patients in rehabilitation department of Fuping County Hospital of Traditional Chinese Medicine as the research group were treated with acupoint plaster improved by Shangjinbitong Powder.After one week of treatment,the effective rates of the two groups were compared.Results:The effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05).There were no adverse reactions such as infection,scald and bleeding in the study group and the control group during the treatment.Conclusion:Shangjinbitong Powder improved acupoint plaster has good curative effect,convenient use,certain safety and clinical popularization value.展开更多
文摘目的:研究筋伤止痛活血散联合经筋刺法对急性软组织损伤后血流变及炎症因子水平的影响。方法:选取2021年3月至2022年7月于我院中医科就诊的急性软组织扭伤患者106例随机分为2组,对照组53例予以治伤软膏联合经筋刺法治疗,试验组53例患者予以筋伤止痛活血散联合经筋刺法治疗。对2组疼痛程度、血液流变学指标、血清炎症因子指标及不良反应发生情况进行比较。结果:试验组治疗有效率96.23%,对照组治疗有效率77.36%,试验组有效率较对照组高(P<0.05)。治疗后,2组患者24、72 h视觉模拟评分(VAS)较治疗前降低(P<0.05);与对照组相比,试验组24、72 h VAS评分较低(P<0.05)。治疗后2组患者血液流变学指标水平较治疗前降低(P<0.05);与对照组相比,试验组血液流变学水平较低(P<0.05)。治疗后,2组患者血清可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)、肿瘤坏死因子-α(TNF-α)水平较治疗前降低(P<0.05);与对照组相比,试验组血清sICAM-1、sVCAM-1、TNF-α水平较低(P<0.05)。对照组与试验组不良反应发生率分别为5.66%、3.77%,无统计学意义(P>0.05)。结论:筋伤止痛活血散联合经筋刺法对于急性软组织损伤患者的止痛效果确切,能调节损伤后血流变指标,抑制炎症反应。
文摘Objective:To study the therapeutic effect of Shangjinbitong Powder(伤筋痹痛散)on improving acupoint plaster,in order to provide some scientific basis for clinical use.Methods:This project was carried out from June 2020 to January 2021,30 patients with low back pain in the outpatient department of orthopedics and traumatology in our hospital and 30 patients with low back pain in the rehabilitation department of Fuping County Hospital of Traditional Chinese Medicine were selected as the research objects.Patients with low back pain in our hospital were treated with Shangjinbitong Powder as the control group,and patients in rehabilitation department of Fuping County Hospital of Traditional Chinese Medicine as the research group were treated with acupoint plaster improved by Shangjinbitong Powder.After one week of treatment,the effective rates of the two groups were compared.Results:The effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05).There were no adverse reactions such as infection,scald and bleeding in the study group and the control group during the treatment.Conclusion:Shangjinbitong Powder improved acupoint plaster has good curative effect,convenient use,certain safety and clinical popularization value.
